Program
V181
A development code. Also written as “V181 High-Potency Level”, “V181 Mid-Potency Level” and “V181 Low-Potency Level”.
Its studies are mostly in Dengue, led by Merck.
Furthest: phase 3, since Jun 2, 20252 company-led studies, 1 open or runningNext primary completion: Sep 6, 2031 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 21 open or running | phase 3since Jun 2, 2025 | Aug 17, 2022 | Sep 6, 2031phase 3 · NCT07013487 |
- Named in Merck’s own pipeline as
V181
, phase 3, as of Nov 2, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2022First study: phase 2 study in Dengue DiseaseFirst studyNCT05507450 · 1,271 enrolled · United States, Australia, Canada and more
- Jun 2, 2025Phase 3 study in HealthyNCT07013487 · 12,000 enrolled · Indonesia, Malaysia, Philippines and more
Ahead
- Sep 6, 2031Primary completion: phase 3 study in HealthyNCT07013487
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid…”study summary, read by Claude · the study
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07013487Healthy · Indonesia, Malaysia, Philippines and more | 3 | Active, not recruiting | Sep 6, 2031 | 12,000 |
| NCT05507450Dengue Disease · United States, Australia, Canada and more | 2 | Completed | Jun 5, 2023 | 1,271 |
How it is read
Names in the registry
- “V181”, 1 entry
- “V181 High-Potency Level”, 1 entry
- “V181 Mid-Potency Level”, 1 entry
- “V181 Low-Potency Level”, 1 entry
Codes read as this program: V181.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.